MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern

Jian Wang,Xu-Guang Yin,Yu Wen,Jie Lu,Ru-Yan Zhang,Shi-Hao Zhou,Chun-Miao Liao,Hua-Wei Wei,Jun Guo
DOI: https://doi.org/10.1021/acs.jmedchem.1c02025
IF: 8.039
2022-02-02
Journal of Medicinal Chemistry
Abstract:Safe and effective vaccines are the best method to defeat worldwide SARS-CoV-2 and its circulating variants. The SARS-CoV-2 S protein and its subunits are the most attractive targets for the development of protein-based vaccines. In this study, we evaluated three lipophilic adjuvants, monophosphoryl lipid A (MPLA), Toll-like receptor (TLR) 1/2 ligand Pam3CSK4, and α-galactosylceramide (α-GalCer), in liposomal and nonliposomal vaccines. The immunological results showed that the MPLA-adjuvanted liposomal vaccine induced the strongest humoral and cellular immunity. Therefore, we further performed a systematic comparison of S-trimer, S-ECD, S1, and RBD as antigens in MPLA-adjuvanted liposomes and found that, although these four vaccines all induced robust specific antibody responses, only S-trimer, S1, and RBD liposomes, but not S-ECD, elicited potent neutralizing antibody responses. Moreover, RBD, S-trimer, and S1 liposomes effectively neutralized variants (B.1.1.7/alpha, B.1.351/beta, P.1/gamma, B.1.617.2/delta, and B.1.1.529/omicron). These results provide important information for the subunit vaccine design against SARS-CoV-2 and its variants.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c02025.Characterization of vaccine liposomes; S-ECD-specific IgG antibody titers measured by ELISA; example flow cytometry plots for CD4+ and CD8+ T cells expressing IFN-γ and TNF-α; specific IgG antibody titers elicited by vaccines against corresponding antigens (PDF)This article is cited by 1 publications.
chemistry, medicinal
What problem does this paper attempt to address?